Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.41 |
| ▸ | MMP3 | P08254 | 4/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432347 | 0.85 | GPR119 (0.51) | GPR119MMP3MMP2MMP13MMP9 | |
| SCHEMBL2216383 | 0.81 | GPR119 (0.45) | GPR119MMP3MMP2MMP13MMP9 | |
| SCHEMBL12434644 | 0.81 | GPR119 (0.45) | GPR119MMP3MMP2MMP13MMP9 | |
| SCHEMBL12106817 | 0.81 | GPR119 (0.44) | GPR119 | |
| SCHEMBL1295002 | 0.80 | GPR119 (0.71) | GPR119MMP13 | |
| SCHEMBL387749 | 0.78 | GPR119 (0.48) | GPR119MMP3 | |
| SCHEMBL1840318 | 0.78 | USP30 (0.42) | GPR119 | |
| SCHEMBL1295590 | 0.77 | GPR119 (0.55) | GPR119LMNASMN1; SMN2 | |
| SCHEMBL1841610 | 0.76 | ADAM17 (0.42) | GPR119ADAM17MMP3MMP2MMP13 | |
| Hydrochloric Acid SCHEMBL1296274 | 0.75 | ADAM17 (0.41) | GPR119ADAM17MMP3MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885ADAM17 3709/4885MMP3 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.